Physician profile
Tao Cui
NPI 1720216336
$3,925.60
in general payments reported to CMS, 2019-2025
24 companies · $899 in 2025
The $899 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $901 · 2022: $930 · 2023: $511 · 2024: $684 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,094.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,245.34 | 2021-2025 | Axonics, Moses, Lumenis Pulse 120h |
| Teleflex LLC | $1,091.56 | 2021-2025 | Urolift, Barrigel |
| Medtronic, INC. | $393.43 | 2022-2025 | Interstim |
| Procept Biorobotics Corporation | $178.56 | 2021 | |
| Axonics, INC. | $124.32 | 2021-2024 | Axonics |
| Urogen Pharma, INC. | $113.81 | 2021 | |
| Convatec INC. | $109.81 | 2022 | |
| Ambu INC. | $103.47 | 2021-2022 | |
| Pfizer INC. | $97.68 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $71.40 | 2024-2025 | Gemtesa, Orgovyx |
| Coloplast Corp | $62.31 | 2023-2025 | Speedicath |
| Endo USA, INC. | $55.79 | 2024-2025 | Aveed, Xiaflex |
| Valencia Technologies Corporation | $37.49 | 2025 | Ecoin Device Kit |
| Exeltis, USA INC. | $33.76 | 2025 | Slynd |
| Srs Medical Systems, INC. | $28.06 | 2021-2024 | Ct3000 Pro Base Unit, Urocuff-Dc Disposable, Single |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $25.07 | 2025 | Trelstar |
| Calyxo, INC. | $24.92 | 2025 | Cvac Aspiration System |
| Astellas Pharma US INC | $23.76 | 2025 | Veozah |
| Millicent US INC | $22.51 | 2024 | Intrarosa, Femring |
| Telix Pharmaceuticals | $22.13 | 2025 | Illuccix |
| Progenics Pharmaceuticals, INC. | $18.64 | 2024 | |
| Olympus America INC. | $17.74 | 2025 | Itind System |
| Ferring Pharmaceuticals INC. | $17.44 | 2025 | Adstiladrin |
| Mayne Pharma Commercial LLC | $6.60 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tao Cui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.